A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.

Détails

ID Serval
serval:BIB_9421CF11AB7C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
A prospective study of the factors shaping antibody responses to the AS03-adjuvanted influenza A/H1N1 vaccine in cancer outpatients.
Périodique
Oncologist
Auteur(s)
Hottinger A.F., George A.C., Bel M., Favet L., Combescure C., Meier S., Grillet S., Posfay-Barbe K., Kaiser L., Siegrist C.A., Dietrich P.Y.
Collaborateur(s)
H1N1 Study Group
Contributeur(s)
Siegrist CA., Posfay-Barbe K., Meier S., Sealy G., Charvat S., Verdon M., Hirschel B., Guerne PA., Seebach J., Dietrich PY., George AC., Hottinger AF., van Delden C., Morard I., Hadaya K., Martin PY., Berney T., Noble S., Nagy M., Roosnek E., Kaiser L., Thomas Y., Wunderli W.
ISSN
1549-490X (Electronic)
ISSN-L
1083-7159
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
17
Numéro
3
Pages
436-445
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
PURPOSE: To identify the determinants of antibody responses to adjuvanted influenza A/H1N1/09 vaccines in a cohort of cancer outpatients.
PATIENTS AND METHODS: Patients with cancer and controls were enrolled in a prospective single-center field study. Two doses of AS03-adjuvanted pandemic influenza vaccine were administered to patients and one dose was administered to controls. Antibody responses were measured using hemagglutination inhibition and confirmed by microneutralization. Geometric mean titers (GMTs) and seroprotection rates (defined as GMTs ≥40) were compared.
RESULTS: Immunizations were safe and well tolerated in 197 cancer patients (lymphoma, 57; glioma, 26; lung or head and neck, 37; gastrointestinal, 41; breast, 36) and 138 controls. Similar seroprotection rates (82.3% versus 87%) and GMTs (336.9 versus 329.9) were achieved after two doses of adjuvanted vaccine in cancer patients and one dose in controls. Univariate analyses identified older age, prior immunization against seasonal influenza, lymphoma, CD4 count, active chemotherapy, and rituximab and steroid treatments as being associated with weaker antibody responses. However, only age and chemotherapy plus rituximab remained independent determinants of vaccine responses in multivariate analyses.
CONCLUSIONS: Two doses of AS03-adjuvanted influenza vaccine elicited potent antibody responses in most cancer patients despite ongoing chemotherapy, with the exception of rituximab-induced B-cell depletion. Oncology patients treated in an outpatient setting benefit from preventive vaccination against influenza with adjuvanted vaccines.
Mots-clé
Age Factors, Aged, Aged, 80 and over, Antibodies/blood, Antibodies/immunology, Antibody Formation/immunology, Female, Humans, Influenza A Virus, H1N1 Subtype/immunology, Influenza Vaccines/administration & dosage, Influenza Vaccines/immunology, Influenza, Human/complications, Influenza, Human/prevention & control, Male, Middle Aged, Neoplasms/complications, Outpatients, Prospective Studies, Sex Factors
Pubmed
Open Access
Oui
Création de la notice
19/02/2014 22:23
Dernière modification de la notice
08/05/2019 22:12
Données d'usage